Jiangsu Huahan Pharmaceutical Technology

Jiangsu Huahan Pharmaceutical Technology is a China-based pharmaceutical company focused on drug development, manufacturing, and commercialization, with an emphasis on licensed or generic cardiovascular medicines. The company was founded in 2019 and is headquartered in Nanjing, Jiangsu. Publicly available sources indicate that Huahan obtained authorization tied to Novartis-origin intellectual property and brought a sacubitril/valsartan sodium tablet product to market in China under the brand name Yuexintuo. The company appears to operate as a small, active pharma business with drug production qualifications and related R&D capabilities rather than as a discovery-stage biotech platform company. Huahan was acquired in 2024 and is now associated with Easywell Biomedicals as an operating subsidiary or controlled affiliate.